Board summary
Key figures
31,511
Registered population
57.5% aged 18–64
23.6%
Aged 65+
ICB 24.3% · England 17.9%
4.3%
Ethnic minority (non-White)
1.8% Asian · England 9.6%
10.8%
In IMD quintile 1
ICB 10.9% · England 21.0%
~3,020
Core20 residents (est.)
Resident basis; registered basis ~3,637 · see page 3
5,747
Hypertension register
+7.12% in 3 yrs · England +5.60%
346
SMI register
20.1% of Herefordshire, County of (LAD)'s
829
COPD register
Reviews -13.08% in 3 yrs
Forecast to 2030
6,839
Hypertension patients, 2030
+1,092 on today
100.0%
QRISK ≥20% on statins, 2030
+13.37pp over 3 yrs
6.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Respiratory annual reviews fell against rising benchmarks.
COPD reviews fell 13.1% over 2023 to 2025 to 70.1% (England +2.8% to 76.4%); asthma reviews are 62.0% (757 unreviewed), which may reflect recall.
Pre-school MMR2 coverage lags 24-month uptake.
In Q1 2025/26, 24-month MMR1 reached 95.8% (target 95.0%), but age-five MMR2 is 87.1%, 6.4 pp below age-five MMR1 at 93.5%.
High-risk lipid therapy rose faster than England.
QRISK ≥ 20% lipid therapy rose 27.3% over 2023 to 2025 to 62.3% (England +6.2% to 63.6%), though 2026 items cost £2.70 (England £1.86).
Population, age and ethnicity
Older patients exceed England levels while Belmont Medical Centre concentrates child cohorts
Across 31,511 registered patients, 23.6% (7,431) are aged 65+, below Herefordshire's 28.3% and the ICB's 24.3%, but above England's 17.9%. Children aged 0–17 comprise 18.9% (5,952), exceeding Herefordshire (16.5%) and the ICB (17.8%) while below England (19.6%), with 22.2% at Belmont Medical Centre, 17.4% at Cantilupe Surgery, and 16.7% at Wargrave House Surgery. Census usual residents in associated areas are 95.7% White (England 81.1%) and 1.8% Asian or Asian British (England 9.6%).
Age profile
65+: ICB 24.3%, England 17.9%
Ethnicity
Older people · falls rows are Herefordshire, County of (LAD) local-authority (LA) data, not PCN
| Measure | Local | West Midlands | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Herefordshire LA) | 1,472 | 1,847 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 77.7% | — | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.0% | — | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Herefordshire LA) | 772 | 922 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Herefordshire LA) | 10.4 | 17.5 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation averages 10.8% across the PCN but reaches 24.9% at Belmont Medical Centre
The PCN Core20 cohort is 10.8%, above Herefordshire (7.8%), in line with the ICB (10.9%), and below England (21.0%). Registered Core20 share is concentrated: Belmont Medical Centre holds 24.9% (2,736 estimated patients), Wargrave House Surgery holds 7.9% (644), and Cantilupe Surgery holds 2.1% (257). Practice-level estimates sum to 3,637 patients, compared with an estimated resident population of 3,020 (about 3,000) across national deciles 1 and 2. Reconciling resident and registered lists is necessary before deploying targeted Core20 outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
346
SMI register
1.10% recorded prevalence
265
Learning disability register
0.84% recorded prevalence
31
Care homes, 879 beds
In the PCN catchment
8.7%
Provide unpaid care
Herefordshire, County of (LAD), Census 2021
Recorded severe mental illness prevalence is 1.1% (346 patients), above Herefordshire (0.9%), the ICB (0.8%) and England (1.0%). Recorded learning disability prevalence is 0.8% (265 patients; Herefordshire 0.6%, ICB 0.6%, England 0.6%). Active care homes in the PCN catchment total 31 with 879 beds, though bed capacity does not establish resident registrations.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.1% (England 1.0%). Recorded blood pressure checks are 76.4% (England 83.4%) and BMI checks are 75.5% (England 82.1%), both trailing national benchmarks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,747
Hypertension register
+7.12%
Register growth, 3 yrs
Herefordshire, County of (LAD) +10.36% · England +5.60%
+1.67pp
BP control, under 80
≤140/90 · +1.33pp aged 80+
+1,092
More patients by 2030
Forecast 6,839 (21.01%)
Hypertension case-finding and control
Hypertension prevalence is 18.3% (5,747 patients), exceeding England (15.2%) but below Herefordshire (19.2%) and the ICB (18.7%). Recorded prevalence is 16.2% at Belmont Medical Centre, 18.5% at Wargrave House Surgery, and 19.9% at Cantilupe Surgery. Crude register comparisons suggest a modelled range of -948 to +296 patients. Treated to target reaches 70.7%, above England (70.3%) and the county (68.6%). Lower recorded prevalence at Belmont Medical Centre could reflect unverified case-mix or detection differences that clinical audits would test.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy is 62.3%, trailing England (63.6%) despite a +27.3% change over 2023 to 2025 (England +6.2%). Statin coverage in diabetes without CVD is 74.8% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than England's rate, making primary prevention recall a potential review area.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 51,016 | £2.70 | £2.17 | £1.86 | £137,743 |
| Cardiovascular (all), 2025 | 64,465 | £4.90 | £4.41 | £3.33 | £315,878 |
For lipid-modifying drugs in 2026, the PCN prescribed 51,016 items at £2.70 per item, exceeding England (£1.86) and the ICB (£2.17). Across these 51,016 items, the PCN spent £42,853 more than at England's unit cost. Higher unit costs than national and system benchmarks highlight an opportunity to review prescribing choices without compromising clinical control.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−4.55%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.59%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.6% (829 patients; England 1.9%), but 12-month reviews reached 70.1% (England 76.4%) and fell 13.1% over 2023 to 2025 (England +2.8%). Asthma prevalence is 6.7% (1,992 patients; England 6.6%), yet 12-month reviews fell 4.5% over 2023 to 2025 (England +4.4%) to 62.0% (England 65.7%), leaving about 760 patients without a recorded review. At Wargrave House Surgery, asthma reviews were 58.5%. Falling review rates are consistent with recall or capacity gaps that workflow audits would test.
Cancer register and children's immunisation
Cancer prevalence is 4.8% (1,502 patients; England 3.8%). In Q1 2025/26, MMR1 coverage at 24 months was 95.8% (0.8 pp above the 95.0% target). At age five, MMR2 coverage was 87.1% (7.9 pp below the 95.0% target), showing a 6.4 pp difference from age-five MMR1 (93.5%). The 4-in-1 pre-school booster was also 87.1% (7.9 pp below target). These gaps could reflect recall timing differences that pre-school audits would test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
56.2%
Herefordshire and Worcestershire ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~770
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Herefordshire and Worcestershire ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 52.4% | 53.2% | 23% | 706 |
| Bowel | 51.4% | 47.0% | 15% | 657 |
| Breast | 88.9% | 85.4% | 28% | 611 |
| Lung | 32.1% | 33.8% | 13% | 473 |
| Skin cancer | 86.3% | 87.8% | 13% | 314 |
In 2022, 56.2% of cancers in NHS Herefordshire and Worcestershire ICB were diagnosed at stage 1 or 2 among cases with a known stage (2,285 of 4,068), compared to 55.3% in England, remaining 18.8 pp below the 75.0% national ambition for 2028 (a gap of 766 cases). Known-stage completeness was 68.0% (4,068 of 5,984 registered cases; England 67.0%). ICB figures describe the wider system, not PCN performance. Locally, PCN breast screening coverage is 67.5% (England 69.9%, ICB 75.0%), with lower rates at Belmont Medical Centre (63.3%) and Wargrave House Surgery (64.7%). Prioritising breast screening recall may help improve timely detection across the system.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Wye Valley NHS Trust achieved 85.1% on the 62-day cancer referral to treatment standard, exceeding Worcestershire Acute Hospitals NHS Trust (53.0%), Gloucestershire Hospitals NHS Foundation Trust (74.6%), NHS Herefordshire and Worcestershire Integrated Care Board (61.7%) and England (71.2%). Wye Valley also reached 86.5% on the 28-day faster diagnosis standard (ICB 83.0%, England 79.3%) and 96.2% on the 31-day standard (ICB 89.9%, England 92.5%). Diagnostic 6+ week waits at Wye Valley were 19.3% overall (Gloucestershire 18.3%, England 23.1%, Worcestershire Acute 30.6%), though colonoscopy waits reached 40.0% (England 30.8%). Provider figures describe system activity, not PCN performance.
| Pathways within standard (%) | Wye Valley | Gloucestershire | Worcestershire Acute | Herefordshire and Worcestershire ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 86.52 | 74.43 | 82.50 | 83.05 | 79.32 |
| 31-day treatment (96%) | 96.25 | 94.66 | 86.98 | 89.95 | 92.50 |
| 62-day referral to treatment (85%) | 85.14 | 74.59 | 52.99 | 61.71 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wye Valley | Gloucestershire | Worcestershire Acute | England |
|---|---|---|---|---|
| MRI | 18.23 | 15.96 | 22.51 | 21.40 |
| CT | 0.16 | 7.44 | 11.09 | 9.92 |
| Echocardiography | 30.24 | 56.17 | 10.25 | 28.48 |
| Colonoscopy | 40.00 | 40.00 | 9.91 | 30.83 |
| Gastroscopy | 26.09 | 31.55 | 9.53 | 29.02 |
| All 15 DM01 tests | 19.35 | 18.34 | 30.61 | 23.14 |
| Community services activity | Herefordshire, County of residents | Herefordshire and Worcestershire ICB |
|---|---|---|
| Care contacts | 43,135 | 124,085 |
| Referrals | 5,970 | 23,130 |
| Patients with a contact | 9,550 | 30,665 |
Community services (residents of Herefordshire, County of), Jun 2026 (provisional). In provisional June 2026 experimental statistics, Herefordshire, County of recorded 5,970 community referrals and 9,550 patients with a community care contact, alongside 23,130 referrals across NHS Herefordshire and Worcestershire Integrated Care Board. Adults aged 65+ represented 67.4% of resident contacts (29,080 of 43,135). These figures reflect wider-system activity across submitting providers rather than PCN-level activity.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF clinical-domain achievement was 100.0% at Cantilupe Surgery, 100.0% at Wargrave House Surgery, and 100.0% at Belmont Medical Centre. The England comparator was 97.1%. For overall achievement, Cantilupe Surgery achieved 99.0%, Wargrave House Surgery achieved 99.2%, and Belmont Medical Centre achieved 93.8%. The England comparator was 92.5%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Cantilupe Surgery | 116 | 2.1 | 61.2% | 70.8% | 82.1% |
| Belmont | 83 | 24.9 | 65.4% | 68.5% | 71.4% |
| Wargrave House | 96 | 7.9 | 36.4% | 58.5% | 61.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Chronic disease reviews fell over three years despite a 27.3% lipid therapy gain
Between 2023 and 2025, the PCN's sharpest relative lags behind England occurred in chronic disease reviews: COPD reviews fell 13.1% (England +2.8%) and heart failure reviews fell 1.0% (England +8.7%), while asthma reviews fell 4.5% (England +4.4%). SMI BMI recording fell 2.8 pp (England +5.1 pp). In contrast, QRISK ≥ 20% lipid therapy rose 27.3% (England +6.2%), while breast screening coverage rose 13.1% over 2023 to 2024 (England +8.4%). These diverging trends could reflect recall or delivery differences that practice audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Heart failure reviews
Asthma reviews
BMI record (SMI)
Alcohol record (psychosis)
QRISK statin treatment
Breast screening (53-70)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Herefordshire, County of (LAD) | Asset | PCN | Herefordshire, County of (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 31 (879 beds) | n/a | Schools (catchment) | 65 | n/a |
| Children's centres | 3 | 7 | Places of worship | 69 | 341 |
| Libraries | 3 | 9 | Day centres (VCS) | 1 | 1 |
| Carers support groups (VCS) | 1 | 1 | Primary schools (LA maintained) | 11 | 43 |
| Primary academies | 12 | 28 | Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD review recall
Asthma reviews are 62.0% (England 65.7%, ICB 66.4%), falling 4.5% over 2023 to 2025 (England +4.4%), a scale gap of 757 across 1,992 registered; COPD reviews are 70.1% (England 76.4%). For discussion: practices could run a single recall template for asthma and COPD reviews, trial flexible slots, and review inhalers. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 2
Combined SMI physical health check outreach
Across 346 SMI patients, BP checks are 76.4% (England 83.4%, falling 0.8 pp vs +4.4 pp) and BMI checks are 75.5% (England 82.1%, falling 2.8 pp vs +5.1 pp). For discussion: audit partial check recording, offer combined appointments or home visits, and raise shared recording with system partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Pre-school MMR2 and booster recall
In Q1 2025/26, age-five MMR2 and 4-in-1 booster coverage are both 87.1% (below the 95.0% target by 7.9 pp), a 6.4 pp difference from age-five MMR1 (93.5%) across 62 children. For discussion: practices could run targeted recall for children with one MMR dose, offer flexible clinics, and review call-recall interfaces. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 list reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Targeted blood pressure case-finding (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Breast screening uptake initiative (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Option 1 · Structured asthma and COPD review recall (p12) | COPD register · COPD patients with a review in the last 12 months · Patients with COPD who had a review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Combined SMI physical health check outreach (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 3 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
